BarryALThornsberryCJonesRN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother1987; 31: 328–30.
2.
LoganMNAshbyJPAndrewsJMWiseR. The in vitro activity and disk susceptibility testing for clarithromycin and its 14-hydroxy metabolite. J Antimicrob Chemother1991; 27: 161–70.
3.
FerreroJLBoppBAMarshKCQuigleySCJohnsonMJAndersonDJ, Metabolism and disposition of clarithromycin in man. Drug Metab Dispos Biol Fate Chem1990; 18: 441–6.
4.
DaveyPG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect1991; 19 (suppl A): 29–37.
5.
McLarenMJMarkowitzMGerberMA. Rheumatic heart disease in developing countries: The consequence of inadequate prevention. Ann Intern Med1994; 120: 243–5.
